Alvotech Humira Settlement Sets Up Interchangeable Adalimumab Showdown
US Launch Date Matches That Of BI’s Cyltezo Interchangeable Humira Biosimilar
Alvotech and AbbVie have settled all of their legal disputes over Alvotech’s AVT02 biosimilar rival to Humira. With Alvotech seeking a coveted interchangeability designation for its higher-strength adalimumab, the firm’s US entry date provided by the settlement matches that of Boehringer Ingelheim’s interchangeable Cyltezo lower-strength adalimumab biosimilar.
